Skip to main content
Erschienen in: Pathology & Oncology Research 4/2019

25.10.2018 | Original Article

Expression of Programmed Death-Ligand 1 in Laryngeal Carcinoma and its Effects on Immune Cell Subgroup Infiltration

verfasst von: Dan Yu, Jinzhang Cheng, Kai Xue, Xue Zhao, Lianji Wen, Chengbi Xu

Erschienen in: Pathology & Oncology Research | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

To study the expression of programmed death-ligand 1 (PD-L1), and its effects on CD8+ tumor infiltrating lymphocytes (TILs) and tumor associated macrophages (TAMs) in human laryngeal squamous cell carcinoma. Sixty-nine patients with laryngeal carcinoma and 10 with vocal cord leukoplakia received tumor resection at Neck Surgery Department in the Second Affiliation Hospital of Jilin University (Changchun, Jilin) from Jan. 2010 to Dec. 2015. The expressions of PD-L1, CD8, CD16 and CD206 in laryngeal carcinoma, paracancerous and vocal cord leukoplakia tissues were detected with immunohistochemistry. The associations between PD-L1 expression and clinicopathologic features, expression of TAMs and CD8+ T cell infiltration were analyzed. Expression of PD-L1 is significantly higher in laryngeal carcinoma than in paracancerous or leukoplakia tissue. The expression of PD-L1 is closely associated with stage of laryngeal cancer, histological differentiation and neck lymphatic metastasis. PD-L1 expression is negatively correlated with the number of CD8+ TILs and CD16+ cells (M1 type TAMs), while is positively associated with CD206+ (M2 type TAMs). PD-L1 is highly expressed in the laryngeal cancer with the tumor microenvironment immunosuppression.
Literatur
1.
Zurück zum Zitat Ferris RL, Whiteside TL, Ferrone S (2006) Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer. Clin Cancer Res 12(13):3890–3895CrossRef Ferris RL, Whiteside TL, Ferrone S (2006) Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer. Clin Cancer Res 12(13):3890–3895CrossRef
2.
Zurück zum Zitat Zandberg DP, Strome SE (2014) The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck. Oral Oncol 50(7):627–632CrossRef Zandberg DP, Strome SE (2014) The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck. Oral Oncol 50(7):627–632CrossRef
3.
Zurück zum Zitat Jinushi M, Komohara Y (2015) Tumor-associated macrophages as an emerging target against tumors: creating a new path from bench to bedside. Biochim Biophys Acta 1855(2):123–130 Jinushi M, Komohara Y (2015) Tumor-associated macrophages as an emerging target against tumors: creating a new path from bench to bedside. Biochim Biophys Acta 1855(2):123–130
4.
Zurück zum Zitat Lee YH, Martin-Orozco N, Zheng P, Li J, Zhang P, Tan H, Park HJ, Jeong M, Chang SH, Kim BS, Xiong W, Zang W, Guo L, Liu Y, Dong ZJ, Overwijk WW, Hwu P, Yi Q, Kwak L, Yang Z, Mak TW, Li W, Radvanyi LG, Ni L, Liu D, Dong C (2017) Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function. Cell Res 27:1034–1045CrossRef Lee YH, Martin-Orozco N, Zheng P, Li J, Zhang P, Tan H, Park HJ, Jeong M, Chang SH, Kim BS, Xiong W, Zang W, Guo L, Liu Y, Dong ZJ, Overwijk WW, Hwu P, Yi Q, Kwak L, Yang Z, Mak TW, Li W, Radvanyi LG, Ni L, Liu D, Dong C (2017) Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function. Cell Res 27:1034–1045CrossRef
5.
Zurück zum Zitat Liu Z, Zhao Y, Fang J, Cui R, Xiao Y et al (2017) SHP2 negatively regulates HLA-ABC and PD-L1 expression via STAT1 phosphorylation in prostate cancer cells. Oncotarget Liu Z, Zhao Y, Fang J, Cui R, Xiao Y et al (2017) SHP2 negatively regulates HLA-ABC and PD-L1 expression via STAT1 phosphorylation in prostate cancer cells. Oncotarget
6.
Zurück zum Zitat Fife BT, Pauken KE, Eagar TN, Obu T, Wu J, Tang Q, Azuma M, Krummel MF, Bluestone JA (2009) Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol 10(11):1185–1192CrossRef Fife BT, Pauken KE, Eagar TN, Obu T, Wu J, Tang Q, Azuma M, Krummel MF, Bluestone JA (2009) Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol 10(11):1185–1192CrossRef
7.
Zurück zum Zitat Zhang L, Li Z, Ding G, La X, Yang P et al (2017) GRP78 plays an integral role in tumor cell inflammation-related migration induced by M2 macrophages. Cell Signal 37:136–148CrossRef Zhang L, Li Z, Ding G, La X, Yang P et al (2017) GRP78 plays an integral role in tumor cell inflammation-related migration induced by M2 macrophages. Cell Signal 37:136–148CrossRef
8.
Zurück zum Zitat Chen J, Li G, Meng H, Fan Y, Song Y, Wang S, Zhu F, Guo C, Zhang L, Shi Y (2012) Upregulation of B7-H1 expression is associated with macrophage infiltration in hepatocellular carcinomas. Cancer Immunol Immunother 61(1):101–108CrossRef Chen J, Li G, Meng H, Fan Y, Song Y, Wang S, Zhu F, Guo C, Zhang L, Shi Y (2012) Upregulation of B7-H1 expression is associated with macrophage infiltration in hepatocellular carcinomas. Cancer Immunol Immunother 61(1):101–108CrossRef
9.
Zurück zum Zitat Gordon SR, Maute RL, Dulken BW, Hutter G, George BM, McCracken MN, Gupta R, Tsai JM, Sinha R, Corey D, Ring AM, Connolly AJ, Weissman IL (2017) PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature 545(7655):495–499CrossRef Gordon SR, Maute RL, Dulken BW, Hutter G, George BM, McCracken MN, Gupta R, Tsai JM, Sinha R, Corey D, Ring AM, Connolly AJ, Weissman IL (2017) PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature 545(7655):495–499CrossRef
10.
Zurück zum Zitat Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, Sharpe AH (2009) PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 206(13):3015–3029CrossRef Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, Sharpe AH (2009) PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 206(13):3015–3029CrossRef
11.
Zurück zum Zitat Yvorel V, Patoir A, Casteillo F, Tissot C, Fournel P, Stachowicz ML, Karpathiou G, Tiffet O, Péoc’h M, Forest F (2017) PD-L1 expression in pleomorphic, spindle cell and giant cell carcinoma of the lung is related to TTF-1, p40 expression and might indicate a worse prognosis. PLoS One 12(7):e0180346CrossRef Yvorel V, Patoir A, Casteillo F, Tissot C, Fournel P, Stachowicz ML, Karpathiou G, Tiffet O, Péoc’h M, Forest F (2017) PD-L1 expression in pleomorphic, spindle cell and giant cell carcinoma of the lung is related to TTF-1, p40 expression and might indicate a worse prognosis. PLoS One 12(7):e0180346CrossRef
12.
Zurück zum Zitat Roper E, Lum T, Palme CE, Ashford B, Ch'ng S, Ranson M, Boyer M, Clark J, Gupta R (2017) PD-L1 expression predicts longer disease free survival in high risk head and neck cutaneous squamous cell carcinoma. Pathology 49:499–505CrossRef Roper E, Lum T, Palme CE, Ashford B, Ch'ng S, Ranson M, Boyer M, Clark J, Gupta R (2017) PD-L1 expression predicts longer disease free survival in high risk head and neck cutaneous squamous cell carcinoma. Pathology 49:499–505CrossRef
13.
Zurück zum Zitat Milstein O, Hagin D, Lask A, Reich-Zeliger S, Shezen E, Ophir E, Eidelstein Y, Afik R, Antebi YE, Dustin ML, Reisner Y (2011) CTLs respond with activation and granule secretion when serving as targets for T-cell recognition. Blood 117(3):1042–1052CrossRef Milstein O, Hagin D, Lask A, Reich-Zeliger S, Shezen E, Ophir E, Eidelstein Y, Afik R, Antebi YE, Dustin ML, Reisner Y (2011) CTLs respond with activation and granule secretion when serving as targets for T-cell recognition. Blood 117(3):1042–1052CrossRef
14.
Zurück zum Zitat Mischinger J, Comperat E, Schwentner C, Stenzl A, Gakis G (2015) Inflammation and Cancer: what can we therapeutically expect from checkpoint inhibitors? Curr Urol Rep 16(9):59CrossRef Mischinger J, Comperat E, Schwentner C, Stenzl A, Gakis G (2015) Inflammation and Cancer: what can we therapeutically expect from checkpoint inhibitors? Curr Urol Rep 16(9):59CrossRef
15.
Zurück zum Zitat Ager CR, Reilley MJ, Nicholas C, Bartkowiak T, Jaiswal AR, Curran MA (2017) Intratumoral STING activation with T cell checkpoint modulation generates systemic antitumor immunity. Cancer Immunol Res 5:676–684CrossRef Ager CR, Reilley MJ, Nicholas C, Bartkowiak T, Jaiswal AR, Curran MA (2017) Intratumoral STING activation with T cell checkpoint modulation generates systemic antitumor immunity. Cancer Immunol Res 5:676–684CrossRef
16.
Zurück zum Zitat Fujii N, Shomori K, Shiomi T, Nakabayashi M, Takeda C, Ryoke K, Ito H (2012) Cancer-associated fibroblasts and CD163-positive macrophages in oral squamous cell carcinoma: their clinicopathological and prognostic significance. J Oral Pathol Med 41(6):444–451CrossRef Fujii N, Shomori K, Shiomi T, Nakabayashi M, Takeda C, Ryoke K, Ito H (2012) Cancer-associated fibroblasts and CD163-positive macrophages in oral squamous cell carcinoma: their clinicopathological and prognostic significance. J Oral Pathol Med 41(6):444–451CrossRef
17.
Zurück zum Zitat Chen C, Qu QX, Shen Y, Mu CY, Zhu YB, Zhang XG, Huang JA (2012) Induced expression of B7-H4 on the surface of lung cancer cell by the tumor-associated macrophages: a potential mechanism of immune escape. Cancer Lett 317(1):99–105CrossRef Chen C, Qu QX, Shen Y, Mu CY, Zhu YB, Zhang XG, Huang JA (2012) Induced expression of B7-H4 on the surface of lung cancer cell by the tumor-associated macrophages: a potential mechanism of immune escape. Cancer Lett 317(1):99–105CrossRef
18.
Zurück zum Zitat Kuang DM, Zhao Q, Peng C, Xu J, Zhang JP, Wu C, Zheng L (2009) Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med 206(6):1327–1337CrossRef Kuang DM, Zhao Q, Peng C, Xu J, Zhang JP, Wu C, Zheng L (2009) Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med 206(6):1327–1337CrossRef
19.
Zurück zum Zitat Kang FB, Wang L, Li D, Zhang YG, Sun DX (2015) Hepatocellular carcinomas promote tumor-associated macrophage M2-polarization via increased B7-H3 expression. Oncol Rep 33(1):274–282CrossRef Kang FB, Wang L, Li D, Zhang YG, Sun DX (2015) Hepatocellular carcinomas promote tumor-associated macrophage M2-polarization via increased B7-H3 expression. Oncol Rep 33(1):274–282CrossRef
20.
Zurück zum Zitat Chen W, Jiang J, Xia W, Huang J (2017) Tumor-related exosomes contribute to tumor-promoting microenvironment: an immunological perspective. J Immunol Res 2017:1073947PubMedPubMedCentral Chen W, Jiang J, Xia W, Huang J (2017) Tumor-related exosomes contribute to tumor-promoting microenvironment: an immunological perspective. J Immunol Res 2017:1073947PubMedPubMedCentral
Metadaten
Titel
Expression of Programmed Death-Ligand 1 in Laryngeal Carcinoma and its Effects on Immune Cell Subgroup Infiltration
verfasst von
Dan Yu
Jinzhang Cheng
Kai Xue
Xue Zhao
Lianji Wen
Chengbi Xu
Publikationsdatum
25.10.2018
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 4/2019
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-018-0501-x

Weitere Artikel der Ausgabe 4/2019

Pathology & Oncology Research 4/2019 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.